Drugs / G-CSF
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05561751 | Feb 2023 → Sep 2025 | plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561751 ↗ |
| Route | Subcutaneous | “will receive SC injections of 10 microgram/kg/day G-CSF” NCT05561751 ↗ |